Free tool
FAERS Monitor: Renova
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021108 or its brand name (Renova, Tretinoin). Reports on generic versions are filed under their own applications.
Reports
6,666
Serious
4,154
62% of reports
Hospitalization
1,431
Death reported
856
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use885
- drug ineffective747
- pain499
- product use in unapproved indication483
- vomiting452
- paraesthesia376
- abdominal pain upper368
- rash367
- nausea353
- diarrhoea350
- headache339
- maternal exposure during pregnancy339
- taste disorder332
- gastrooesophageal reflux disease329
- drug intolerance327
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 38 |
| 2005 | 33 |
| 2006 | 28 |
| 2007 | 40 |
| 2008 | 115 |
| 2009 | 76 |
| 2010 | 80 |
| 2011 | 95 |
| 2012 | 160 |
| 2013 | 106 |
| 2014 | 150 |
| 2015 | 246 |
| 2016 | 364 |
| 2017 | 358 |
| 2018 | 473 |
| 2019 | 364 |
| 2020 | 383 |
| 2021 | 430 |
| 2022 | 510 |
| 2023 | 569 |
| 2024 | 676 |
| 2025 | 810 |
| 2026 | 562 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,047,493 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| taste disorderSignal | 332 | 52.5 | 47.2 | 16,456 |
| gastrooesophageal reflux diseaseSignal | 329 | 12.9 | 11.6 | 3,613 |
| maternal exposure during pregnancySignal | 339 | 12.0 | 10.9 | 3,423 |
| drug intoleranceSignal | 327 | 10.7 | 9.6 | 2,874 |
| paraesthesiaSignal | 376 | 7.6 | 6.8 | 2,143 |
| product use in unapproved indicationSignal | 483 | 6.2 | 5.7 | 2,103 |
| abdominal pain upperSignal | 368 | 5.6 | 5.1 | 1,414 |
| off label useSignal | 885 | 3.2 | 3.0 | 1,386 |
| vomitingSignal | 452 | 3.0 | 2.8 | 628 |
| rashSignal | 367 | 2.7 | 2.4 | 386 |
| painSignal | 499 | 2.6 | 2.4 | 489 |
| drug ineffective | 747 | 1.8 | 1.7 | 276 |
| diarrhoea | 350 | 1.7 | 1.5 | 106 |
| headache | 339 | 1.7 | 1.5 | 101 |
| nausea | 353 | 1.4 | 1.3 | 43 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.